Sab biotherapeutics receives australian approval to commence phase 1 clinical trial of sab-142, a potential disease-modifying treatment for type 1 diabetes

Australian human research ethics committee (hrec) grants approval for sab to begin first-in-human phase 1 clinical study of sab-142, the first fully human anti-thymocyte immunoglobulin (atg)

SABS Ratings Summary

SABS Quant Ranking